Cytokinetics, Inc. (CYTK) Posts Q2 EPS Loss of $0.23, Well Below Expectations
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $69.92 +0.76%
EPS Growth %: +43.1%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: +43.1%
Financial Fact:
Total revenues: 59.05M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $6.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Radiant Logistics (RLGT) Tops Q4 EPS by 9c
- RH (RH) Tops Q2 EPS by $2.31
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
